---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056885"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:19:22.949738+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M

## Summary
- Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.
- Advanced Wound Care revenue $103.9M (+3%); Surgical & Sports Medicine $6.1M (-9%).
- GAAP net loss $2.1M ($0.02 EPS); adjusted net loss $1.4M; Adjusted EBITDA $2.6M.
- FY2024 guidance reaffirmed: revenue $445M-$470M; adjusted EBITDA $15.8M-$35M.
- Cash $89.3M, debt $64.9M as of March 31, 2024.

## SEC filing metadata
- accession: 0000950170-24-056885
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017024056885/0000950170-24-056885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017024056885/orgo-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056885
- JSON: https://secwatch.observer/filing/0000950170-24-056885.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056885.txt

## Key facts
- Earnings Releases
  Organogenesis Holdings Inc. reported first quarter ended March 31, 2024 results: revenue $110.0 million, net income $2.1 million, EPS $(0.02) per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $110.0 million
  - Net income: $2.1 million
  - EPS: $(0.02) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: • Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenue of $107.6 million for the first quarter of 2023. Net revenue for the first quarter of 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661181/000095017024056885/0000950170-24-056885-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.